

Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 3, 2022 [/PRNewswire/](#) -- [Nuvalent, Inc.](#) (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the Canaccord Genuity 42^d Annual Growth Conference on Wednesday, August 10, 2022, at 4:00 p.m. ET in Boston.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter ([@nuvalent](#)) and [LinkedIn](#).

SOURCE Nuvalent, Inc.

Investor Contact

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact

Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

<https://investors.nuvalent.com/2022-08-03-Nuvalent-to-Present-at-the-Canaccord-Genuity-42nd-Annual-Growth-Conference>